Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that...
In a pioneering clinical trial that will attack Alzheimer’s disease by targeting inflammation in the brain’s blood vessels, researchers at the George & Anne Ryan Institute for Neuroscience have received regulatory approval to initiate the BEACON Study. This...
Sound Pharmaceuticals (SPI) is pleased to announce that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with SPI-1005 is aimed to prevent and treat ototoxicity in Cystic Fibrosis (CF) patients...
A research consortium recently began enrolling patients in a clinical trial examining whether fecal microbiota transplantation (FMT) by enema–putting stool from a healthy donor in the colon of a recipient–is safe and can prevent recurrent Clostridium...
A research consortium of NIH recently began enrolling patients in a clinical trial examining whether fecal microbiota transplantation (FMT) by enema—putting stool from a healthy donor in the colon of a recipient is safe and can prevent recurrent Clostridium...
Email
Text